British switch specialist Maxwellia has received an injection of funding via the the BioCity angel investment platform, which it says will be used to support prescription-to-OTC reclassifications in the area of women’s health and wellness.
Two of these switches were currently undergoing the approval process with the Medicines and Healthcare products Regulatory Agency (MHRA), BioCity revealed, moving Maxwellia – the “world’s first Rx-to-OTC switch incubator” –
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?